Related references
Note: Only part of the references are listed.SHP2 protects endothelial cell barrier through suppressing VE-cadherin internalization regulated by MET-ARF1
Jie Zhang et al.
FASEB JOURNAL (2019)
Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells
Lufeng Zheng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Src and SHP2 coordinately regulate the dynamics and organization of vimentin filaments during cell migration
Cheng-Yi Yang et al.
ONCOGENE (2019)
Excitatory neuron-specific SHP2-ERK signaling network regulates synaptic plasticity and memory
Hyun-Hee Ryu et al.
SCIENCE SIGNALING (2019)
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Hengyu Lu et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling
Eunhee Choi et al.
NATURE COMMUNICATIONS (2019)
Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis
Hua Zhao et al.
ONCOGENE (2019)
SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors
Tamer A. Ahmed et al.
CELL REPORTS (2019)
MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression
Zhen Cai et al.
ARCHIVES OF ORAL BIOLOGY (2018)
STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling
Lufeng Zheng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Sara Mainardi et al.
NATURE MEDICINE (2018)
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
Leila Dardaei et al.
NATURE MEDICINE (2018)
Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-gamma production in tumor microenvironment
P. Xiao et al.
ONCOGENE (2018)
IL22 Promotes Kras-Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of Sternness Properties
Nasim Khosravi et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Status of KRAS in iPSCs Impacts upon Self-Renewal and Differentiation Propensity
Kenji Kubara et al.
STEM CELL REPORTS (2018)
SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
Carmine Fedele et al.
CANCER DISCOVERY (2018)
EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
Jianlin Xu et al.
SCIENTIFIC REPORTS (2016)
Lung cancer: Biology and treatment options
Hassan Lemjabbar-Alaoui et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2015)
The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
Peter M. K. Westcott et al.
NATURE (2015)
Cancer Stemness in Apc- vs. Apc/KRAS-Driven Intestinal Tumorigenesis
Mehrnaz Ghazvini et al.
PLOS ONE (2013)
Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors
Woo-Young Kim et al.
CANCER (2012)
Share Paper
